Bucindolol single dose pharmacokinetics (PK) in subjects with impaired hepatic function.

被引：0
|
作者：
Ogunremi, A
Gehr, T
Sica, D
Sellers, J
Roberge, P
Ward, D
机构：
[1] Incara Pharmaceut, Res Triangle Pk, NC USA
[2] Virginia Commonwealth Univ, Div Nephrol, Richmond, VA USA
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2000年 / 67卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
PIII65
引用
收藏
页码：158 / 158
页数：1
相关论文
共 50 条
  • [1] The single-dose pharmacokinetics of carisbamate in subjects with normal and impaired hepatic function.
    Moore, K. T.
    Zannikos, P.
    Solanki, B.
    Greenspan, A.
    Romano, G.
    Brashear, H.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2008, 83 : S24 - S24
  • [2] The multiple dose pharmacokinetics of cilansetron in subjects with normal and impaired hepatic function.
    Pardue, RL
    Zipfel, L
    Fritsch, H
    Brennan, J
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2003, 73 (02) : P78 - P78
  • [3] Comparative pharmacokinetics of multiple-dose candesartan in subjects with and without impaired hepatic function.
    Dingemanse, J
    Kleinbloesem, CH
    Hoogkamer, JFW
    Ouwerkerk, M
    Hogemann, A
    Nokhodian, A
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1997, 61 (02) : PII61 - PII61
  • [4] PHARMACOKINETICS OF CARIPRAZINE IN HEALTHY SUBJECTS AND PATIENTS WITH IMPAIRED HEPATIC FUNCTION.
    Lee, Y.
    Periclou, A.
    Kapas, M.
    Laszlovszky, I.
    Ghahramani, P.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2014, 95 : S51 - S51
  • [5] PHARMACOKINETICS OF DAPRODUSTAT AND METABOLITES IN SUBJECTS WITH NORMAL AND IMPAIRED HEPATIC FUNCTION.
    Shaddinger, B.
    Andrews, S.
    Mahar, K.
    Ramanjineyulu, B.
    Caltabiano, S.
    Lindsay, A.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2020, 107 : S92 - S92
  • [6] Single-Dose Pharmacokinetics of Boceprevir in Subjects with Impaired Hepatic or Renal Function
    Treitel, Michelle
    Marbury, Thomas
    Preston, Richard A.
    Triantafyllou, Ilias
    Feely, William
    O'Mara, Edward
    Kasserra, Claudia
    Gupta, Samir
    Hughes, Eric A.
    CLINICAL PHARMACOKINETICS, 2012, 51 (09) : 619 - 628
  • [7] Single-Dose Pharmacokinetics of Boceprevir in Subjects with Impaired Hepatic or Renal Function
    Michelle Treitel
    Thomas Marbury
    Richard A. Preston
    Ilias Triantafyllou
    William Feely
    Edward O’Mara
    Claudia Kasserra
    Samir Gupta
    Eric A. Hughes
    Clinical Pharmacokinetics, 2012, 51 (9) : 619 - 628
  • [8] Bucindolol (B) single dose pharmacokinetics (PK) in subjects with varying degrees of renal impairment.
    Ogunremi, A
    Swan, S
    Gehr, T
    Sica, D
    Sellers, J
    Roberge, P
    Ward, D
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2000, 67 (02) : 158 - 158
  • [9] Riluzole single dose pharmacokinetics in patients with impaired liver function.
    Patat, A
    Kirkesseli, S
    Lefebvre, P
    Calic, F
    Montay, G
    Le Coz, F
    Gandon, JM
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1998, 63 (02) : 188 - 188
  • [10] EVALUATION OF THE PHARMACOKINETICS, SAFETY, AND TOLERABILITY OF A SINGLE DOSE OF ALDAFERMIN IN SUBJECTS WITH IMPAIRED HEPATIC FUNCTION
    Li, Yan
    Chan, Ming Liang
    Harr, Mihoko
    Rondon, Juan
    Marbury, Thomas C.
    Lawitz, Eric J.
    Ling, Lei
    Willett, Michael S.
    HEPATOLOGY, 2022, 76 : S663 - S664
12345